Citadel Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Citadel Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1	Closed	-$76K	–	8229
2016 Q3	$76K	Hold	1	–	–	﹤0.01%	6745
2016 Q2	$86K	Sell	1 -1	-50%	-$118K	﹤0.01%	6254
2016 Q1	$263K	Buy	+2	New	+$215K	﹤0.01%	5272
2015 Q4	–	Hold	0	–	-$43K	–	9508
2015 Q3	–	Sell	-1	Closed	-$234K	–	7688
2015 Q2	$189K	Buy	+1	New	+$264K	﹤0.01%	6400

Other funds holding NVIV

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's NVIV Position: Q4 2022 in Review

Citadel Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2022, closing a stake of 42,794 shares — an estimated $184K sold.

Citadel Advisors first reported a position in NVIV in Q1 2019 and held it in 6 quarters. The position peaked at $184K in Q3 2022. 18 funds tracked by Wall St. Rank hold NVIV as of Q4 2022.

Citadel Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 42,794 InVivo Therapeutics Holdings Corp shares in Q4 2022, an estimated $184K.
Citadel Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q1 2019 and held it in 6 quarters.
Citadel Advisors's InVivo Therapeutics Holdings Corp position peaked at $184K in Q3 2022.
18 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.